Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search span> per sponsor: Celgene
Woman and Man
Between 18 years
and 99 years
Celgene
Update Il y a 5 ans
Etude CC-486-MDS-006 : étude randomisée de phase 2 visant à évaluer l’efficacité et la sécurité d’une association d’azacitidine et de durvalumab chez des patients ayant un syndrome myélodysplasique. [essai clos aux inclusions]
Les syndromes myélodysplasiques (SMD) forment un ensemble de maladies caractérisées par la production insuffisante de cellules sanguines matures saines par la moelle osseuse. Les cellules sanguines im...
Country
France
organs
Syndromes myélodysplasiques (SMD)
Specialty
Chimiothérapie
,
Immunothérapie - Vaccinothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 5 ans
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects with Acute Myeloid Leukemia (AML) no longer experiences symptoms of the disease
The primary objective of the study is to evaluiate whether maintenance therapy with oral azacitidine improves OS compared with placebo in subjects with AML, age ≥55 years, who have achieved first CR o...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 5 ans
A study to evaluate the drug Mongersen (GED-0301) for the treatment of Crohn’s disease
To evaluate the efficacy of GED-0301 compared with placebo on clinical activity at 12 Weeks, in subjects with active Crohn’s disease (CD).
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 5 ans
A multi center study to assess the safety and efficacy of nab-paclitaxel with CC-486, nab-paclitaxel with MEDI4736 and nab-paclitaxel alone as 2nd/3rd line treatment in subjects with advanced NSCLC
To estimate the efficacy of nab-paclitaxel administered intravenously (IV) on Days 8 and 15 with epigenetic modifying therapy of CC-486 once daily (QD) on Days 1 to 14 every 21 days or nab-paclitaxel ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 5 ans
To determine the safety, clinical efficacy, and effect of azacitidine on the body,within the body and interactions within the body in children and young adults with newly diagnosed advanced Myelodysplastic Syndromes or Juvenile myelomonocyctic leukemia before transplantation of the bone marrow and blood. At the end of the study, the data will be compared to data from an older study of patients with the same diseases
The primary objective is to assess the treatment effect on response rate (MDS: CR, PR, or marrow CR; JMML: either cCR or cPR) at Cycle 3 Day 28 and to compare against standard therapy using a matched-...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Celgene
Update Il y a 5 ans
AZA-ST-001 : Essai de phase 1 évaluant le CC-486 en monothérapie ou en association avec le carboplatine ou l’ABI-007, chez des patients ayant une tumeur solide en rechute ou réfractaire. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer la tolérance et de déterminer la dose d’azacitidine orale à administrer en monothérapie ou en association avec le carboplatine ou l’ABI-007, chez des patients aya...
Country
France
organs
Tumeurs solides
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 5 ans
A study using a new drug (GED-0301) to investigate if the new drug works and is safe in subjects suffering ulcerative colitis
To explore the effect of GED-0301 on clinical activity, as measured by the MMS in subjects with active UC.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Celgene International II Sàrl
Update Il y a 5 ans
A study to assess the safety and tolerability of durvalumab as monotherapy and in combination therapy in people with lymphoma or chronic lymphocytic leukemia
Dose finding part (Phase 1): - To assess the safety and tolerability of durvalumab when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab to determine the...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 5 ans
A Phase 2 placebo-controlled study to compare the effectiveness and safety of two doses of apremilast (CC-10004) in subjects with active rheumatoid arthritis, who have not responded to methotrexate treatment
The primary objective is to evaluate the efficacy of two doses of apremilast (20 mg BID and 30 mg BID) compared with placebo on the reduction of signs and symptoms of RA at 24 weeks of treatment
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 5 ans
A Phase 3 study of the safety and effectiveness of Apremilast versus placebo in patients with moderate to severe plaque psoriasis Studio di fase 3 per valutare l`efficacia e la sicurezza di Apremilast in pazienti affetti da psoriasi a placche moderata e grave
Evaluate the clinical efficacy of apremilast 30 mg BID, compared with placebo, in subjects with moderate to severe plaque psoriasis Valutare l'efficacia clinica di apremilast 30 mg BID, rispett...
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
3
4
5
6
7
8
9
10
Next